Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

p>

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that pixantrone could cause cumulative heart damage, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room


    Investors Contact:

    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... Boston, MA (PRWEB) January 22, 2015 ... systems, is pleased to announce an exciting product from a ... of motion analysis solutions over the past 15 years, with ... industries. Most recently, their 3D IMU system (inertial measurement unit), ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... (NYSE: AOB ) today announced that it ... conditions and other factors, to sell,approximately $125 million ... stock. The convertible preferred stock is,contingently putable, will ... upon the occurrence of specified events into cash, ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) today ... its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and,SYMLIN(R) ... drug candidates at the American Diabetes Association,s 68th ... CA from June 6 to,10. The company will ...
... HERmark and HER1 and HER3 Total Protein ... Assays in Collaborative Biomarker Study, ... Inc. (Nasdaq: MGRM ) today announced that scientific,collaborators ... oncology assay, as a means to measure HER2 total,protein ...
Cached Biology Technology:American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 4Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 5Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 6Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 7Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 2Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 3Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 4Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 5Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 6
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... that opens up the complex world of climate change and ... global award for a team from the University of Southampton. ... international ,Apps for Climate, competition (#Apps4Climate) held by the World ... By opening up the facts of climate change in different ...
... Bangladesh prefer inexpensive, traditional stoves for cooking over modern ... study in the Proceedings of the National Academy ... percentbelieved that indoor smoke from the traditional stoves is ... and spoiled food (66 percent). Still, Bangladeshi women opted ...
... SPring-8 Angstrom Compact free-electron Laser (SACLA) appeared online in ... second XFEL facility comes in response to its record-breaking ... the world (0.63 Angstroms), an extremely broad wavelength range ... output of 10 GW. SACLA achieves this performance despite ...
Cached Biology News:Revealing climate change website wins global award 2Bangladeshi women prefer pollution-causing cookstoves 2
...
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
... The TRAPeze RT Telomerase ... sensitive in vitro assay for ... time quantification of telomerase activity. ... original TRAPeze assay and adds ...
... kit for 10 chips provides the chips ... with the Experion automated electrophoresis system. This ... x 520 microliters Pro260 gel, 45 microliters ... kD), 400 microliters Pro260 sample buffer, and ...
Biology Products: